{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:03:54Z","timestamp":1784178234717,"version":"3.55.0"},"reference-count":86,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Endometriosis is a chronic estrogen-dependent condition affecting women of reproductive age and commonly presents with dysmenorrhea, chronic pelvic pain, dyspareunia, and infertility. In a substantial proportion of patients, pain persists despite first-line hormonal treatment, making alternative pharmacologic strategies necessary. GnRH agonists and antagonists act primarily by suppressing ovarian estrogen production and thereby reduce an important hormonal driver of disease activity. Although both classes are effective for pain relief, they differ in onset of action, reversibility, tolerability, and suitability for prolonged use. This narrative review summarizes the current evidence on GnRH-based therapies for endometriosis-associated pain, with particular attention to biological rationale, clinical efficacy, safety, and the role of add-back therapy. Overall, both agonists and antagonists appear to provide clinically significant symptom improvement, especially in women who do not respond adequately to oral contraceptives or progestins. Their clinical use, however, is limited by hypoestrogenic adverse effects such as vasomotor symptoms and bone mineral density loss, which often require monitoring and adjunctive add-back therapy. Oral GnRH antagonists may offer practical advantages in selected patients through rapid action, the absence of a flare effect, and dose-adjustable hormonal suppression, although treatment choice must also consider long-term safety, cost, access, and individual patient characteristics. In summary, GnRH analogues remain useful second-line options, but treatment should be individualized according to symptom severity, previous treatment response, reproductive goals, tolerability, bone health, cost, and availability.<\/jats:p>","DOI":"10.3390\/jcm15145440","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:53:58Z","timestamp":1783932838000},"page":"5440","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GnRH Analogues for the Treatment of Endometriosis-Related Pain: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3786-1061","authenticated-orcid":false,"given":"Costin Vlad","family":"Anastasiu","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Specialties, Faculty of Medicine, Transilvania University of Brasov, 500019 Brasov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9407-389X","authenticated-orcid":false,"given":"Oana Gabriela","family":"Dimienescu","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Faculty of Medicine, Transilvania University of Brasov, 500019 Brasov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Dull","sequence":"additional","affiliation":[{"name":"Regina Maria Hospital, 500091 Brasov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-3914","authenticated-orcid":false,"given":"Ovidiu Dan","family":"Grigorescu","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Faculty of Medicine, Transilvania University of Brasov, 500019 Brasov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Canditu","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Faculty of Medicine, Transilvania University of Brasov, 500019 Brasov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-6917","authenticated-orcid":false,"given":"Marius Alexandru","family":"Moga","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Faculty of Medicine, Transilvania University of Brasov, 500019 Brasov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0140-6736(10)60490-4","article-title":"Endometriosis and infertility: Pathophysiology and management","volume":"376","author":"Borghese","year":"2010","journal-title":"Lancet"},{"key":"ref_2","first-page":"182","article-title":"Patients with chronic pelvic pain: Endometriosis or interstitial cystitis\/painful bladder syndrome?","volume":"11","author":"Butrick","year":"2007","journal-title":"JSLS"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Agarwal, S.K., Chapron, C., Giudice, L.C., Laufer, M.R., Leyland, N., Missmer, S.A., Singh, S.S., and Taylor, H.S. (2019). Clinical diagnosis of endometriosis: A call to action. Am. J. Obstet. Gynecol., 220.","DOI":"10.1016\/j.ajog.2018.12.039"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0002-9378(96)70438-6","article-title":"Are there any clinical signs and symptoms that are related to endometriosis in infertile women?","volume":"174","author":"Matorras","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrendo.2013.255","article-title":"Endometriosis: Pathogenesis and treatment","volume":"10","author":"Vercellini","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13625180701387266","article-title":"Pathogenesis of endometriosis: The role of defective immunosurveillance","volume":"12","author":"Christodoulakos","year":"2007","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Oal\u0103, I.E., Mitranovici, M.I., Chiorean, D.M., Irimia, T., Cri\u0219an, A.I., Melinte, I.M., Cotru\u0219, T., Tudorache, V., Moraru, L., and Moraru, R. (2024). Endometriosis and the role of pro-inflammatory and anti-inflammatory cytokines in pathophysiology: A narrative review of the literature. Diagnostics, 14.","DOI":"10.3390\/diagnostics14030312"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e18761429315431","DOI":"10.2174\/0118761429315431240712100124","article-title":"The role of local angiotensin II\/angiotensin type 1 receptor in endometriosis: A potential target for new treatment approaches","volume":"17","author":"Moazen","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1472-6483(10)61590-8","article-title":"Use of GnRH antagonists in the treatment of endometriosis","volume":"5","author":"Kupker","year":"2002","journal-title":"Reprod. Biomed. Online"},{"key":"ref_10","first-page":"e38136","article-title":"Gonadotropin-releasing hormone GnRH receptors and their role in the treatment of endometriosis","volume":"15","author":"Resta","year":"2023","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1701-2163(16)34589-3","article-title":"Endometriosis: Diagnosis and management","volume":"32","author":"Leyland","year":"2010","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.fertnstert.2006.03.057","article-title":"Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis","volume":"86","author":"Anaf","year":"2006","journal-title":"Fertil. Steril."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"McNamara, H.C., Frawley, H.C., Donoghue, J.F., Readman, E., Healey, M., Ellett, L., Reddington, C., Hicks, L.J., Harlow, K., and Rogers, P.A.W. (2021). Peripheral, central, and cross sensitization in endometriosis-associated pain and comorbid pain syndromes. Front. Reprod. Health, 3.","DOI":"10.3389\/frph.2021.729642"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/humrep\/dev147","article-title":"Pain typology and incident endometriosis","volume":"30","author":"Schliep","year":"2015","journal-title":"Hum. Reprod."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/humupd\/dmu021","article-title":"Peripheral changes in endometriosis-associated pain","volume":"20","author":"Morotti","year":"2014","journal-title":"Hum. Reprod. Update"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2147\/JPR.S168715","article-title":"Perineural invasion in endometriotic lesions contributes to endometriosis-associated pain","volume":"11","author":"Liang","year":"2018","journal-title":"J. Pain. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0015-0282(02)03331-9","article-title":"Relation between pain symptoms and the anatomic location of deep infiltrating endometriosis","volume":"78","author":"Fauconnier","year":"2002","journal-title":"Fertil. Steril."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tem.2014.10.003","article-title":"Inflammation and nerve fiber interaction in endometriotic pain","volume":"26","author":"McKinnon","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Chen, Y., and Li, T. (2025). Unveiling the mechanisms of pain in endometriosis: Comprehensive analysis of inflammatory sensitization and therapeutic potential. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041770"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.tips.2015.03.004","article-title":"Menstruation pulls the trigger for inflammation and pain in endometriosis","volume":"36","author":"Zollner","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12974-017-0828-3","article-title":"Macrophage and nerve interaction in endometriosis","volume":"14","author":"Wu","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/en.2017-00562","article-title":"Early endometriosis in females is directed by immune-mediated estrogen receptor alpha and IL-6 cross-talk","volume":"159","author":"Burns","year":"2018","journal-title":"Endocrinology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29069","DOI":"10.3390\/ijms161226151","article-title":"Mast cell-mediated mechanisms of nociception","volume":"16","author":"Aich","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/humrep\/del077","article-title":"Effects of peritoneal fluid from endometriosis patients on the release of vascular endothelial growth factor by neutrophils and monocytes","volume":"21","author":"Na","year":"2006","journal-title":"Hum. Reprod."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/me.2009-0017","article-title":"Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1\/2, AKT, NF-kappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms","volume":"23","author":"Banu","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5114\/ceji.2015.50840","article-title":"Pro-inflammatory cytokines for evaluation of inflammatory status in endometriosis","volume":"40","author":"Malutan","year":"2015","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3892\/mmr.2024.13167","article-title":"Angiogenesis signaling in endometriosis: Molecules, diagnosis and treatment (review)","volume":"29","author":"Bo","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2741\/E40","article-title":"Role of cytokines in the endometrial-peritoneal cross-talk and development of endometriosis","volume":"1","author":"Kyama","year":"2009","journal-title":"Front. Biosci. (Elite Ed.)"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1210\/en.2007-1168","article-title":"Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms","volume":"149","author":"Banu","year":"2008","journal-title":"Endocrinology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/humupd\/dmu025","article-title":"Central changes associated with chronic pelvic pain and endometriosis","volume":"20","author":"Brawn","year":"2014","journal-title":"Hum. Reprod. Update"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Golinska, M., Wo\u0142yniak, M., Kulesza, P., and Fendler, W. (2025). Neuroinflammation is responsible for pain in endometriosis-targeting the JAK-STAT pathway and mast cell activation. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1621178"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.neuroscience.2007.07.053","article-title":"Neural mechanisms of pelvic organ cross-sensitization","volume":"149","author":"Malykhina","year":"2007","journal-title":"Neuroscience"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Velho, R.V., Freitag, J.H., Brueckner, A.M., Thalmeier, L., Pohl, J., and Mechsner, S. (2026). The histamine-associated inflammatory landscape of endometriosis: Molecular profiling of HDC, HRH1-HRH4, and cytokines across lesion subtypes. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27010212"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1933719110391279","article-title":"TRPV1 expression on peritoneal endometriosis foci is associated with chronic pelvic pain","volume":"18","author":"Rocha","year":"2011","journal-title":"Reprod. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1093\/humrep\/del260","article-title":"Nerve fibres in peritoneal endometriosis","volume":"21","author":"Tokushige","year":"2006","journal-title":"Hum. Reprod."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/humrep\/17.7.1895","article-title":"Hyperalgesia, nerve infiltration and nerve growth factor expression in deep adenomyotic nodules, peritoneal and ovarian endometriosis","volume":"17","author":"Anaf","year":"2002","journal-title":"Hum. Reprod."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-physiol-012110-142158","article-title":"Endometriosis: The role of neuroangiogenesis","volume":"73","author":"Asante","year":"2011","journal-title":"Annu. Rev. Physiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/gutjnl-2011-300306","article-title":"Visceral hypersensitivity in endometriosis: A new target for treatment?","volume":"61","author":"Issa","year":"2012","journal-title":"Gut"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12958-025-01471-3","article-title":"Macrophages in endometriosis: Key roles and emerging therapeutic opportunities-A narrative review","volume":"23","author":"Wang","year":"2025","journal-title":"Reprod. Biol. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1074-3804(99)80006-1","article-title":"Correlation between endometriosis and pelvic pain","volume":"6","author":"Porpora","year":"1999","journal-title":"J. Am. Assoc. Gynecol. Laparosc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s44294-025-00110-x","article-title":"Circulating inflammatory biomarkers and endometriosis lesion characteristics in the WisE Consortium","volume":"3","author":"Terry","year":"2025","journal-title":"npj Womens Health"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0015-0282(16)56039-7","article-title":"A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis","volume":"60","author":"Vercellini","year":"1993","journal-title":"Fertil. Steril."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/2230-8210.85575","article-title":"Gonadotropin releasing hormone agonists: Expanding vistas","volume":"15","author":"Magon","year":"2011","journal-title":"Indian. J. Endocrinol. Metab."},{"key":"ref_44","first-page":"CD008475","article-title":"Gonadotrophin-releasing hormone analogues for pain associated with endometriosis","volume":"2023","author":"Brown","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/0974-1208.142476","article-title":"Gonadotropin-releasing hormone analogs: Understanding advantages and limitations","volume":"7","author":"Kumar","year":"2014","journal-title":"J. Hum. Reprod. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00006250-199805000-00029","article-title":"Leuprolide acetate depot and hormonal add-back in endometriosis: A 12-month study","volume":"91","author":"Marik","year":"1998","journal-title":"Obstet. Gynecol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0015-0282(16)55205-4","article-title":"An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis","volume":"58","author":"Shaw","year":"1992","journal-title":"Fertil. Steril."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0002-9378(90)90433-8","article-title":"Nafarelin in the treatment of pelvic pain caused by endometriosis","volume":"162","author":"Shaw","year":"1990","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/GCO.0b013e32833b35a7","article-title":"Gonadotropin-releasing hormone agonist and add-back therapy: What do the data show?","volume":"22","author":"Surrey","year":"2010","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Donnez, J., and Dolmans, M.-M. (2021). GnRH antagonists with or without add-back therapy: A new alternative in the management of endometriosis?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111342"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM198802253180805","article-title":"Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial","volume":"318","author":"Henzl","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0015-0282(16)53574-2","article-title":"A comparison of nafarelin acetate and danazol in the treatment of endometriosis","volume":"53","author":"Kennedy","year":"1990","journal-title":"Fertil. Steril."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/0002-9378(90)90437-C","article-title":"Nafarelin versus danazol in the treatment of endometriosis","volume":"162","author":"Rolland","year":"1990","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0015-0282(99)00636-6","article-title":"Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): A pilot study with low-dose agonist therapy (\u201cdraw-back\u201d therapy)","volume":"73","author":"Tahara","year":"2000","journal-title":"Fertil. Steril."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"The Nafarelin European Endometriosis Trial Group (NEET) (1992). Nafarelin for endometriosis: A large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. Fertil. Steril., 57, 514\u2013522.","DOI":"10.1016\/S0015-0282(16)54893-6"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1726-4901(09)70166-2","article-title":"A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan","volume":"68","author":"Cheng","year":"2005","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0015-0282(16)53755-8","article-title":"Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized, placebo-controlled, double-blind study","volume":"54","author":"Dlugi","year":"1990","journal-title":"Fertil. Steril."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0002-9378(11)91718-9","article-title":"Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis","volume":"167","author":"Wheeler","year":"1992","journal-title":"I. Effic. Results. Am. J. Obstet. Gynecol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0002-9378(93)90126-4","article-title":"Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: A multicenter double-blind randomized clinical trial","volume":"169","author":"Wheeler","year":"1993","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_60","first-page":"431","article-title":"A randomized comparative study of the effect of Leuprolide acetate depot and danazol in the treatment of endometriosis","volume":"57","author":"Chang","year":"1996","journal-title":"Zhonghua YI Xue ZA Zhi (Free China Ed.)"},{"key":"ref_61","first-page":"51","article-title":"Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis","volume":"93","author":"Ling","year":"1999","journal-title":"Obstet. Gynecol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0029-7844(97)00620-0","article-title":"Leuprolide acetate depot and hormonal add-back in endometriosis: A 12-month study","volume":"91","author":"Hornstein","year":"1998","journal-title":"Obstet. Gynecol."},{"key":"ref_63","first-page":"709","article-title":"Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: Long-term follow-up","volume":"99","author":"Surrey","year":"2002","journal-title":"Obstet. Gynecol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0015-0282(16)55073-0","article-title":"Goserelin (Zoladex) depot in the treatment of endometriosis","volume":"57","author":"Reichel","year":"1992","journal-title":"Fertil. Steril."},{"key":"ref_65","first-page":"198","article-title":"Zoladex (goserelin acetate implant) in the treatment of endometriosis: A randomized comparison with danazol","volume":"82","author":"Rock","year":"1993","journal-title":"Obstet. Gynecol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Australian New Zealand ZOLADEX Study Group (1996). Goserelin depot versus danazol in the treatment of endometriosis: The Australian\/New Zealand experience. Aust. N. Z. J. Obstet. Gynaecol., 36, 55\u201360.","DOI":"10.1111\/j.1479-828X.1996.tb02924.x"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/humrep\/deh035","article-title":"The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: A prospective randomized trial","volume":"19","author":"Soysal","year":"2004","journal-title":"Hum. Reprod."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/jwh.2019.8096","article-title":"A clinician\u2019s guide to the treatment of endometriosis with elagolix","volume":"30","author":"Leyland","year":"2021","journal-title":"J. Womens Health"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000002675","article-title":"Long-term outcomes of elagolix in women with endometriosis: Results from two extension studies","volume":"132","author":"Surrey","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/1933719113497292","article-title":"Elagolix treatment for endometriosis-associated pain: Results from a phase 2, randomized, double-blind, placebo-controlled study","volume":"21","author":"Diamond","year":"2014","journal-title":"Reprod. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Miller, C.E., Kim, J.H., Kroll, R., Simon, J.A., Soliman, A.M., Thomas, J.W., Xu, Y., Ng, J., and Snabes, M.C. (2024). Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: Twelve months of an ongoing randomized phase 3 trial. Am. J. Obstet. Gynecol., 231.","DOI":"10.1016\/j.ajog.2024.06.040"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.fertnstert.2024.06.009","article-title":"Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain","volume":"122","author":"Abrao","year":"2024","journal-title":"Fertil. Steril."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/humrep\/dead263","article-title":"Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study","volume":"39","author":"Becker","year":"2024","journal-title":"Hum. Reprod."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Osuga, Y., Seki, Y., Tanimoto, M., Kusumoto, T., Kudou, K., and Terakawa, N. (2021). Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: Phase 2 safety and efficacy 24-week results. BMC Womens Health, 21.","DOI":"10.1186\/s12905-021-01393-3"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(22)00622-5","article-title":"Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: Two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.fertnstert.2020.07.055","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: A randomized, double-blind, placebo-controlled study","volume":"115","author":"Osuga","year":"2021","journal-title":"Fertil. Steril."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.fertnstert.2021.11.013","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with Leuprolide in Japanese women: A phase 3, randomized, double-blind, noninferiority study","volume":"117","author":"Harada","year":"2022","journal-title":"Fertil. Steril."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.fertnstert.2020.02.114","article-title":"Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: A randomized clinical trial","volume":"114","author":"Donnez","year":"2020","journal-title":"Fertil. Steril."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/humrep\/deae076","article-title":"Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: A prospective, randomized, double-blind, phase 3 study (EDELWEISS 3)","volume":"39","author":"Donnez","year":"2024","journal-title":"Hum. Reprod."},{"key":"ref_81","first-page":"40","article-title":"GnRH agonists in the treatment of symptomatic endometriosis: A review","volume":"4","author":"Surrey","year":"2023","journal-title":"F S Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1471-0528.1999.tb08366.x","article-title":"A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis","volume":"106","author":"Vercellini","year":"1999","journal-title":"BJOG"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Kaveh, M., Chaichian, S., Kashi, A.M., Mohsenikia, M., Afrouzeh, M., and Sadegi, K. (2025). Comparison of quality of life in patients with endometriosis undergoing treatment with progestins, oral contraceptives pills (OCP), and GnRH agonists. BMC Womens Health, 25.","DOI":"10.1186\/s12905-025-03937-3"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0002-9378(88)90128-7","article-title":"Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis","volume":"158","author":"Lemay","year":"1988","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.7150\/ijbs.116635","article-title":"Unravelling the intricate link: Mast cells and estrogen-induced pain sensitization in endometriosis","volume":"21","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"hoac009","DOI":"10.1093\/hropen\/hoac009","article-title":"ESHRE guideline: Endometriosis","volume":"2022","author":"Becker","year":"2022","journal-title":"Hum. Reprod. Open"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5440\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:21:23Z","timestamp":1784175683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":86,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145440"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145440","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]}}}